JP2003199588A5 - - Google Patents

Info

Publication number

JP2003199588A5

JP2003199588A5 JP2002283631A JP2002283631A JP2003199588A5 JP 2003199588 A5 JP2003199588 A5 JP 2003199588A5 JP 2002283631 A JP2002283631 A JP 2002283631A JP 2002283631 A JP2002283631 A JP 2002283631A JP 2003199588 A5 JP2003199588 A5 JP 2003199588A5

Authority

JP

Japan

Prior art keywords

polypeptide

polynucleotide

amino acid

recombinant vector

peptide

Prior art date

2002-09-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000765 processed proteins & peptides Proteins 0.000 description 49
• 229920001184 polypeptide Polymers 0.000 description 38
• 102000004196 processed proteins & peptides Human genes 0.000 description 38
• 239000002157 polynucleotide Substances 0.000 description 26
• 102000040430 polynucleotide Human genes 0.000 description 25
• 108091033319 polynucleotide Proteins 0.000 description 25
• 125000003275 alpha amino acid group Chemical group 0.000 description 13
• 125000000539 amino acid group Chemical group 0.000 description 10
• 150000001875 compounds Chemical class 0.000 description 8
• 230000009504 deubiquitination Effects 0.000 description 8
• 230000000694 effects Effects 0.000 description 7
• 238000000034 method Methods 0.000 description 7
• 230000000295 complement effect Effects 0.000 description 6
• 239000005557 antagonist Substances 0.000 description 5
• 239000002773 nucleotide Substances 0.000 description 4
• 150000001413 amino acids Chemical class 0.000 description 3
• 239000003814 drug Substances 0.000 description 3
• 230000004770 neurodegeneration Effects 0.000 description 3
• 208000015122 neurodegenerative disease Diseases 0.000 description 3
• 125000003729 nucleotide group Chemical group 0.000 description 3
• 230000001766 physiological effect Effects 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
• 238000007792 addition Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• 230000003449 preventive effect Effects 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 206010028289 Muscle atrophy Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 230000020763 muscle atrophy Effects 0.000 description 1
• 201000000585 muscular atrophy Diseases 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 230000014616 translation Effects 0.000 description 1